Entera Bio (ENTX) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entera Bio (ENTX) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 32.8% versus a loss of 57.8%. Over five years, ENTX leads with a -44.5% price change compared with -55.8% for SPRY. Entera Bio is the larger company by market cap ($436.3 million vs $433.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | SPRY |
|---|---|---|
| Share price | $2.51 | $4.36 |
| Market cap | $436.32M | $433.59M |
| 1-day change | -0.79% | +1.51% |
| YTD return | +29.38% | -62.58% |
| 1-year return | +32.80% | -57.79% |
| 5-year return | -44.47% | -55.78% |
| EPS (TTM) | $-0.36 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $13.15 |
| 52-week low | $0.91 | $3.99 |
| Distance from 52-week high | -40.24% | -66.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +288.45% | +416.06% |
| Average volume | 1.81M | 1.86M |
| Shares outstanding | 173.83M | 99.45M |
| Employees | 20 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed SPRY by 90.6 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
ENTX vs SPRY FAQ
Which is bigger, Entera Bio or ARS Pharmaceuticals?
Entera Bio (ENTX) is larger, with a market capitalization of $436.32M compared with $433.59M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, ENTX or SPRY?
ENTX returned +32.80% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and ARS Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Entera Bio and Biotechnology: Pharmaceutical Preparations for ARS Pharmaceuticals.